About Zinc finger protein 611
Zinc finger protein 611 (ZNF611) is a protein
from Homo sapiens identified by UniProt accession
Q8N823, 705 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
Disease associations (25)
Diseases linked to this target (Open Targets).
- Red cell distribution width · score 0.30
- genetic disorder · score 0.12
- Shwachman-Diamond syndrome · score 0.03
- atypical hemolytic-uremic syndrome with C3 anomaly · score 0.03
- atypical hemolytic-uremic syndrome with MCP/CD46 anomaly · score 0.03
- atypical hemolytic-uremic syndrome with I factor anomaly · score 0.03
- atypical hemolytic-uremic syndrome with thrombomodulin anomaly · score 0.03
- Blackfan-Diamond anemia · score 0.03
- tubulointerstitial kidney disease, autosomal dominant, 2 · score 0.03
- atypical hemolytic-uremic syndrome with B factor anomaly · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Experimental structures are not indexed in MolForge yet —
search RCSB PDB for Q8N823.
Amino-acid sequence (705 residues)
MLREEAAQKR KGKEPGMALP QGRLTFRDVA IEFSLAEWKC LNPSQRALYR EVMLENYRNL EAVDISSKCM MKEVLSTGQG NTEVIHTGTL QRHESHHIGD FCFQEIEKEI HDIEFQCQED ERNGLEAPMT KIKKLTGSTD QHDHRHAGNK PIKDQLGSSF YSHLPELHIF QIKGEIGNQL EKSTNDAPSV STFQRISCRP QTQISNNYGN NPLNSSLLPQ KQEVHMREKS FQCNKSGKAF NCSSLLRKHQ IPHLGDKQYK CDVCGKLFNH EQYLACHDRC HTVEKPYKCK ECGKTFSQES SLTCHRRLHT GVKRYNCNEC GKIFGQNSAL LIDKAIDTGE NPYKCNECDK AFNQQSQLSH HRIHTGEKPY KCEECDKVFS RKSTIETHKR IHTGEKPYRC KVCDTAFTWH SQLARHRRIH TAKKTYKCNE CGKTFSHKSS LVCHHRLHGG EKSYKCKVCD KAFVWSSQLA KHTRIDCGEK PYKCNECGKT FGQNSDLLIH KSIHTGEQPY KCDECEKVFS RKSSLETHKI GHTGEKPYKC KVCDKAFACH SYLAKHTRIH SGEKPYKCNE CSKTFSHRSY LVCHHRVHSG EKPYKCNECS KTFSRRSSLH CHRRLHSGEK PYKCNECGNT FRHCSSLIYH RRLHTGEKSY KCTICDKAFV RNSLLSRHTR IHTAEKPYKC NECGKAFNQQ SHLSRHHRIH TGEKP
Explore Zinc finger protein 611 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets